Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.

Title: Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Authors: Nikitas, John; Rettig, Matthew; Shen, John; Reiter, Robert; Lee, Alan; Steinberg, Michael; Valle, Luca; Sachdeva, Ankush; Romero, Tahmineh; Calais, Jeremie; Czernin, Johannes; Nickols, Nicholas; Kishan, Amar
Source: European Urology, vol 85, iss 6
Publisher Information: eScholarship, University of California
Publication Year: 2024
Collection: University of California: eScholarship
Subject Terms: Abiraterone acetate; Androgen annihilation therapy; Apalutamide; Leuprolide; Metastasis-directed therapy; Oligorecurrence; Prostate cancer; Stereotactic body radiotherapy; Humans; Male; Prostatic Neoplasms; Aged; Radiosurgery; Neoplasm Recurrence; Local; Middle Aged; Thiohydantoins; Prednisone; Prostate-Specific Antigen; Neoplasm Metastasis; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Androgen Antagonists; Treatment Outcome; Antineoplastic Agents; Hormonal
Description: Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy. Patients received 6mo of androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) and metastasis-directed SBRT. The primary endpoint was the percentage of patients with prostate-specific antigen (PSA)
Document Type: article in journal/newspaper
File Description: application/pdf
Language: unknown
Relation: qt3k18x9ps; https://escholarship.org/uc/item/3k18x9ps; https://escholarship.org/content/qt3k18x9ps/qt3k18x9ps.pdf
DOI: 10.1016/j.eururo.2024.01.021
Availability: https://escholarship.org/uc/item/3k18x9ps; https://escholarship.org/content/qt3k18x9ps/qt3k18x9ps.pdf; https://doi.org/10.1016/j.eururo.2024.01.021
Rights: public
Accession Number: edsbas.9D700231
Database: BASE